MedTrace Logo

Clinical and Biological Markers in Acute Respiratory Failure

NCT02019095 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2015-02-03

No results posted yet for this study

Summary

In a recent experimental study, the investigators showed that the growth factor Activin A is expressed in the lungs of rats with the acute respiratory distress syndrome (ARDS) at levels that are comparable with those determined in the bronchoalveolar (BAL) lavage fluid from patients with ARDS. In the same study, the administration of the Activin A inhibitor Folistatin resulted in attenuation of the histological damage of the ARDS-afflicted rat lung.

The precise role of Activin A/Folistatin in acute respiratory failure associated with acute lung inflammatory pathology has not been elucidated yet. Therefore, the purpose of the present, observational study is to investigate the role of Activin A/Folistatin in respiratory failure due to ARDS and/or ventilator-associated pneumonia (VAP), also in relation with other biochemical markers, such as cytokines and surfactant-related proteins.

Conditions

  • Ventilator-Associated Pneumonia
  • Acute Respiratory Distress Syndrome

Interventions

OTHER

Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid

Sponsors & Collaborators

  • Academy of Athens

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Spyros D Mentzelopoulos, MD, PhD · Evaggelismos General Hospital; Dept. Intensive Care Medicine, University of Athens Medical School

  • Spyros G Zakynthinos, MD, PhD · Evaggelismos General Hospital; Dept. Intensive Care Medicine, University of Athens Medical School

  • Spyros G Zakynthinos, MD, PhD · Evaggelismos General Hospital; Dept. Intensive Care Medicine, University of Athens Medical School

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02019095 on ClinicalTrials.gov